Venous Thromboembolism Prophylaxis and Treatment in Pregnancy

Agent Selection

• The American College of Chest Physicians (ACCP) recommends low‑molecular‑weight heparin (LMWH; enoxaparin or dalteparin) as the preferred anticoagulant for both prophylaxis and treatment of VTE in pregnancy because it is more effective, safer, and more convenient than unfractionated heparin (Grade 1A) 1, 2, 3.
• Vitamin K antagonists (warfarin) are contraindicated throughout pregnancy due to the risk of embryopathy and fetal bleeding (Grade 1A) 1, 2.
• Direct oral anticoagulants should be avoided in pregnancy because safety data are insufficient (Grade 1C) 3.

Risk Stratification for Ante‑partum Prophylaxis

High‑Risk Patients (Require LMWH)

• Women with a history of unprovoked VTE should receive prophylactic‑ or intermediate‑dose LMWH for the entire pregnancy (Grade 2C) 1, 2.
• Women whose prior VTE was related to pregnancy or estrogen exposure also require prophylactic‑ or intermediate‑dose LMWH throughout gestation (Grade 2C) 1, 2.
• Women with multiple prior unprovoked VTE episodes who are not on chronic anticoagulation need prophylactic‑ or intermediate‑dose LMWH during pregnancy (Grade 2C) 1, 2.
• Women on chronic vitamin K antagonist therapy should be switched to an adjusted LMWH dose equal to 75 % of the therapeutic dose for the whole pregnancy and resume long‑term anticoagulation after delivery (Grade 2C) 1, 2.

Thrombophilia‑Specific Indications

• Homozygous factor V Leiden or prothrombin G20210A mutation together with a positive family history of VTE warrants prophylactic‑dose LMWH during pregnancy (Grade 2C) 1, 2.

Low‑Risk Patients (No Routine Prophylaxis)

• Women with a single prior VTE that was provoked by a transient, non‑pregnancy factor (e.g., surgery or trauma) should receive clinical vigilance only; routine LMWH prophylaxis is not indicated (Grade 2C) 1, 2.

Dosing Regimens

Prophylactic Dosing (Standard Risk)

• Enoxaparin 40 mg subcutaneously once daily throughout pregnancy (Grade 2C) 3.
• Dalteparin 5,000 units subcutaneously once daily throughout pregnancy (Grade 2C) 3.

Intermediate Dosing (Moderate‑High Risk)

• Enoxaparin 40 mg subcutaneously every 12 hours, or dose‑adjusted to achieve anti‑Xa levels of 0.2–0.6 U/mL (Grade 2C) 3.

Adjusted‑Dose Therapeutic LMWH (Acute VTE or Very High Risk)

• Enoxaparin 1 mg/kg subcutaneously every 12 hours, or 1.5 mg/kg once daily (Grade 2C) 1, 2.
• For women already on chronic anticoagulation, use 75 % of the therapeutic LMWH dose throughout pregnancy (Grade 2C) 1, 2.

Peripartum Management

• LMWH should be discontinued at least 24 hours before any planned induction of labor, cesarean delivery, or neuraxial anesthesia to reduce bleeding risk (Grade 1B) 1, 2, 4.
• In spontaneous labor, LMWH should be withheld as soon as uterine contractions begin (Grade 1B) 1, 2.
• Therapeutic anticoagulation may be resumed 12–24 hours after delivery once hemostasis is confirmed (Grade 1B) 1, 2.

Post‑partum Prophylaxis

• All women with any prior VTE should receive 6 weeks of post‑partum prophylaxis with prophylactic‑ or intermediate‑dose LMWH (or warfarin targeting INR 2.0–3.0) regardless of ante‑partum management (Grade 2B) 1, 2, 4.
• This recommendation also applies to women whose prior VTE was low‑risk and who did not receive ante‑partum prophylaxis (Grade 2B) 1, 2.

Cesarean Section‑Specific Prophylaxis

Standard‑Risk Cesarean (No Additional Risk Factors)

• Early mobilization alone is sufficient; pharmacologic prophylaxis is not recommended (Grade 1B) 1, 2, 4.

Increased‑Risk Cesarean (≥1 Major or ≥2 Minor Risk Factors)

• Prophylactic LMWH (enoxaparin 40 mg once daily) or mechanical prophylaxis (sequential compression devices or elastic stockings) should be provided while the patient is hospitalized (Grade 2B) 1, 2, 4.
• Mechanical methods are preferred when anticoagulation is contraindicated because of bleeding risk (Grade 2B) 1, 2, 4.

Very‑High‑Risk Cesarean (Multiple Persistent Risk Factors)

• Combine prophylactic LMWH with elastic stockings and/or intermittent pneumatic compression rather than LMWH alone (Grade 2C) 1, 2, 4.
• Extend prophylaxis up to 6 weeks after discharge if risk factors persist (Grade 2C) 1, 2, 4.

Treatment of Acute VTE During Pregnancy

• Adjusted‑dose subcutaneous LMWH is preferred over adjusted‑dose unfractionated heparin for acute VTE treatment (Grade 1B) 1, 2, 4.
• LMWH is also preferred to vitamin K antagonists for antenatal VTE management (Grade 1A) 1, 2, 4.
• Anticoagulation should be continued for at least 6 weeks after delivery, with a minimum total treatment duration of 3 months (Grade 2C) 1, 2, 4, 3.

Special Populations

• Women who develop severe ovarian hyperstimulation syndrome should receive prophylactic LMWH for 3 months after resolution of the syndrome (Grade 2C) 4.

Common Pitfalls to Avoid

• Do not withhold post‑partum prophylaxis in women with prior VTE; a 6‑week course of LMWH remains indicated even if ante‑partum prophylaxis was not given (Grade 2B) 1, 2.
• Do not continue LMWH up to the time of delivery; stopping at least 24 hours before planned delivery reduces the risk of severe bleeding and epidural hematoma (Grade 1B) 1, 2, 4.
• Do not assume that all thrombophilias require ante‑partum prophylaxis; only high‑risk thrombophilias (homozygous mutations, compound heterozygosity, antithrombin deficiency) or those with a prior VTE merit LMWH during pregnancy (Grade 2C) 1, 2.

Prophylactic Low Molecular Weight Heparin in Pregnancy

History of Prior VTE

• Women with prior unprovoked or hormone-related VTE should receive antepartum prophylactic or intermediate-dose LMWH throughout pregnancy, as recommended by the American College of Chest Physicians 5, 6
• Women with multiple prior unprovoked VTE episodes not on long-term anticoagulation require antepartum prophylactic or intermediate-dose LMWH, according to the American College of Chest Physicians 7, 8
• Women on long-term vitamin K antagonists should receive adjusted-dose LMWH (75% of therapeutic dose) throughout pregnancy, as suggested by the American College of Chest Physicians 7, 8

Thrombophilia-Related Indications

• Antithrombin deficiency with family history of VTE warrants both antepartum and postpartum prophylaxis, as recommended by the American Society of Hematology 5
• Homozygosity for factor V Leiden mutation requires antepartum and postpartum prophylaxis regardless of family history, according to the American Society of Hematology 5, 9
• Combined thrombophilias (compound heterozygosity) warrant antepartum and postpartum prophylaxis regardless of family history, as recommended by the American Society of Hematology 5, 9

Assisted Reproductive Technology

• Women who develop severe ovarian hyperstimulation syndrome should receive prophylactic LMWH for 3 months post-resolution, as suggested by the American College of Chest Physicians 7, 10

Postpartum Prophylaxis After Cesarean Section

• Women with one major risk factor or at least two minor risk factors should receive prophylactic LMWH or mechanical prophylaxis (if anticoagulation contraindicated) during hospitalization, according to the American College of Chest Physicians 7, 8
• Extended prophylaxis up to 6 weeks postpartum is suggested for women with persistent multiple risk factors after discharge, as recommended by the American College of Chest Physicians 7, 8

Universal Postpartum Prophylaxis for Prior VTE

• All women with any history of prior VTE should receive 6 weeks of postpartum prophylaxis with prophylactic or intermediate-dose LMWH, or warfarin (INR 2.0-3.0), as recommended by the American College of Chest Physicians 7, 8

Practical Dosing Considerations

• LMWH is preferred over unfractionated heparin for all prophylactic indications in pregnancy (Grade 1B), according to the American College of Chest Physicians 7, 10
• Routine anti-Xa monitoring is NOT recommended for prophylactic dosing, as suggested by the American Society of Hematology 5
• LMWH should be discontinued at least 24 hours before planned delivery or neuraxial anesthesia, according to the American College of Chest Physicians 7, 8

LMWH Management in Early IVF Pregnancy with Subchorionic Hematoma

General Recommendations

• The American College of Chest Physicians (ACCP) recommends low‑molecular‑weight heparin (LMWH) as the preferred anticoagulant throughout pregnancy for women who require thromboprophylaxis; the presence of mild vaginal bleeding or a subchorionic hematoma does not automatically require discontinuation when the indication for anticoagulation remains valid. 11
• LMWH does not cross the placenta and carries no direct fetal teratogenic risk, making it the safest anticoagulant option during the first trimester when organogenesis occurs. 11
• ACCP states that LMWH is preferred over unfractionated heparin for both prevention and treatment of venous thromboembolism (VTE) in pregnancy because of superior efficacy, safety profile, and convenience (Grade 1B). 11

Indications for LMWH in IVF Pregnancies

• The primary indications for LMWH in IVF‑related pregnancies include documented thrombophilia, recurrent pregnancy loss, or a history of prior thrombotic events; withdrawing anticoagulation in these settings is associated with substantial maternal and fetal morbidity. 12

When to Continue vs. Hold LMWH

• Continue LMWH unless there is evidence of hemodynamic instability, severe hemorrhage requiring transfusion, or a rapidly expanding hematoma that threatens pregnancy viability (per ACCP). 11
• Temporarily hold LMWH if the patient experiences active heavy vaginal bleeding defined as soaking more than one pad per hour for more than two consecutive hours. 11
• Temporarily hold LMWH if hemoglobin drops by more than 2 g/dL or if the patient develops hemodynamic instability requiring resuscitation. 11

Contraindicated Substitutes and Dose Reductions

• Switching to aspirin alone is not recommended; aspirin does not provide adequate thromboprophylaxis for women with documented thrombophilia or prior VTE and has no role as monotherapy in this context. 11
• Empirically reducing the LMWH dose below the standard prophylactic regimen (e.g., enoxaparin 40 mg daily) based solely on the presence of a subchorionic hematoma is discouraged, as sub‑prophylactic dosing may fail to prevent thrombotic complications and offers no proven reduction in bleeding risk. 11

Duration of Therapy

• ACCP advises continuation of prophylactic LMWH throughout the entire pregnancy and for at least six weeks postpartum (minimum total duration of three months) when the original indication was a prior VTE or high‑risk thrombophilia. 11
• LMWH should be discontinued at least 24 hours before any planned delivery or neuraxial anesthesia to minimize bleeding risk at the time of birth. 11